Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 113Neoplasms 8HER2-positive Breast Cancer 8Neoplasm Metastasis 6Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Inflammatory Breast Neoplasms 4Hematologic Neoplasms 3Brain Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Salivary Gland Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Locally Advanced Breast Cancer 2HER2-positive Metastatic Breast Cancer 2HER2-positive Early Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2Urinary Bladder Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Skin Neoplasms 1Sarcoma 1

Interventions

pertuzumab 2Trastuzumab 2Carboplatin 2pyrotinib 1Taxes 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HER2-positive Early Breast Cancer × pertuzumab × Clear all
NCT07340398 2026-01-21

TAYLOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
200 enrolled
Breast

HER2-positive Early Breast Cancer

NCT04750122 2021-04-01

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

Peking University People's Hospital

Phase 1/2 Recruiting
46 enrolled
Breast

HER2-positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡